Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Clinical Chemistry

• Publication date

  1998-02-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1093/CLINCHEM/44.2.408PMID 9474052
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.

  1997cited by this paper
• Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.

  1997cited by this paper
• GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever

  1997cited by this paper
• G‐CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta‐analysis and pharmacoeconomic evaluation

  1996cited by this paper
• Prospective audit of costs and outcome of aminoglycoside treatment and of therapy for gram-negative bacteraemia.

  1995cited by this paper
• Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia

  1994cited by this paper
• The Costs of Treating Febrile Neutropenia in Patients with Malignant Blood Disorders

  1994cited by this paper
• Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule.

  1994cited by this paper
• Cost Considerations in Therapeutic Drug Monitoring of Aminoglycosides

  1994cited by this paper
• Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy.

  1994cited by this paper
• Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms.

  1994cited by this paper
• Assessment of Cost-Effective Antibiotic Therapy in the Management of Infections in Cancer Patients

  1994cited by this paper
• The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.

  1993cited by this paper
• The costs of treating febrile neutropenia in six U.K. Hospitals.

  1993cited by this paper
• Management of fever in patients with cancer and treatment-induced neutropenia.

  1993cited by this paper
• Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer

  1993cited by this paper
• Guidelines for performing a pharmacoeconomic analysis.

  1992cited by this paper
• Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins

  1992cited by this paper
• Kikuchi's disease revisited.

  1992cited by this paper
• Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness.

  1991cited by this paper
• Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever—Reply

  1991cited by this paper
• Does Accepting Pharmacokinetic Recommendations Impact Hospitalization? A Cost‐Benefit Analysis

  1990cited by this paper
• From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.

  1990cited by this paper
• Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides: A Cost‐Benefit Analysis

  1990cited by this paper
• Response rates to a staged antibiotic regimen in febrile neutropenic patients.

  1988cited by this paper
• Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients

  1986cited by this paper
• Neutropenia, fever, and infection.

  1984cited by this paper
• The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

  1984cited by this paper
• Increased burn patient survival with individualized dosages of gentamicin.

  1982cited by this paper
• Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost--benefit analysis.

  1979cited by this paper
• Experience in Monitoring Gentamicin Therapy during Treatment of Serious Gram-Negative Sepsis

  1974cited by this paper

• The future role of laboratory medicine in hospitals 1

  2010cites this paper
• Die zukünftige Rolle des Krankenhauslabors / The future role of laboratory medicine in hospitals

  2010cites this paper
• Evidence of endemic goiter and iodine deficiency in a mountainous area of Haiti.

  2009cites this paper
• Miscellaneous antibacterial drugs

  2007cites this paper
• Medical Devices: Competitiveness and Impact on Public Health Expenditure

  2005cites this paper
• Therapeutic drug monitoring: is it cost-effective?

  2002cites this paper
• Therapeutic Drug Monitoring

  2001cites this paper
• DOSE ÚNICA VERSUS DOSE FRACIONADA DIÁRIA DE GENTAMICINA: CONCENTRAÇÃO DE GENTAMICINA NA BILE E SUA RELAÇÃO COM A CONCENTRAÇÃO INIBITÓRIA MÍNIMA DAS BACTÉRIAS RESPONSÁVEIS PELAS INFECÇÕES DAS VIAS BILIARES.

  2000cites this paper